Following the events of February 11, 160 Health (02656.HK) has once again experienced a massive single-day plunge.

NewTimeSpace understands that prior to the crash on March 18, 160 Health’s share price had broken through HK$150, with its market capitalization surpassing the HK$50 billion mark. As of the close on March 18, the company was quoted at HK$103.40, representing a single-day decline of 31.52%, with its market value shrinking to HK$34.79 billion.

Positive Performance Realized? Over HK$10 Billion in Market Value Wiped Out in a Day

Since its inclusion in the Southbound Stock Connect on March 9, 160 Health’s share price has seen a continuous rally.

Data shows that in the seven trading days since March 9, 160 Health’s share price surged by 115%, making it one of the most eye-catching companies in the recent Hong Kong stock market. As of the close on March 17, 2026, 160 Health stood at HK$151 per share, nearly a 1,200% cumulative increase compared to its IPO price of HK$11.89 on September 17, 2025, with its market value crossing the HK$50 billion threshold.

However, 160 Health’s share price took a sharp dive from its peak on March 18, 2026. By the close of trading on March 18, 2026, the company was quoted at HK$103.40, down 31.52% for the day. Its market capitalization stood at HK$34.79 billion, representing a staggering loss of HK$16.02 billion in a single day.

Yesterday evening, 160 Health released its latest financial results. The announcement indicated that for the year ending December 31, 2025, the company expects to record an adjusted net profit between RMB 3 million and RMB 5 million, compared to an adjusted net loss of RMB 31.5 million for the year ending December 31, 2024. This marks the company's first-ever full-year profit, primarily attributed to year-on-year revenue growth and a significant reduction in operating expenses.

NewTimeSpace has learned that prior to this earnings announcement, 160 Health reported positive progress in its digital healthcare solutions business for 2025. The company announced that in 2025, it reached "160 AI Hospital" operational cooperation agreements with 82 public Grade II Class A and above hospitals, a year-on-year increase of over 720% compared to 2024. Notably, 52 new public hospitals were added in the fourth quarter of 2025 alone, achieving a quarter-on-quarter growth of 420%.

Furthermore, the recent explosive popularity of OpenClaw has turned AI healthcare agents from a concept into reality, further fueling the heat of the AI medical sector.

On March 10, 160 Health announced that the Group, relying on an integrated "Platform + AI Agent + Operation" model, is gradually deploying "Medical Digital Employee" systems for medical institutions, promoting the practical application of AI agents, represented by OpenClaw, in medical scenarios.

The strong stock performance of 160 Health in recent days was driven by a series of positive catalysts. Following the release of the 2025 results, the company's fundamental performance and value assessment may have entered a new stage.

Two Major Pillars: AI Healthcare Business Becomes Key to Profitability

Public information shows that 160 Health, founded in 2005, is a pharmaceutical and healthcare product wholesaler and a leading digital healthcare integrated service provider.

NewTimeSpace understands that 160 Health's core business consists of two main parts. The first is Digital Healthcare Solutions, which includes its original business—providing medical institutions with IT systems for appointment registration, online consultation, and internet hospital operations—as well as the market-envisioned AI hospital solutions. The second major segment is Drug Sales. Through online platforms and offline channels, 160 Health provides wholesale and retail services for drugs, healthcare products, and medical devices to users.

The gross margin for the first business segment is very high, reaching 80.9% in 2025, making it the company’s primary source of profit. Conversely, the gross margin for drug sales is relatively low and has declined annually, from 4.1% in 2022 to 1.4% in 2025.

Looking at 160 Health's previous business performance, the pharmaceutical sales business contributed 70% of total revenue. Due to the low gross margins, 160 Health has suffered losses for several consecutive years since 2020, with a cumulative loss exceeding RMB 500 million.

It was not until the arrival of the AI wave that 160 Health achieved a turnaround, bolstered by the concept and empowerment of AI healthcare.

In the turnaround announcement on March 17, 160 Health stated that the full-year profit was driven by a slight increase in gross profit from revenue growth, coupled with a significant reduction in annual operating expenses following refined management and improved operational efficiency. The company stated it has fully introduced AI agents into its internal operations, which are currently applied to product R&D, content production, and customer service systems, shortening the product iteration cycle by over 60%.

Surrounded by Giants: AI Strategic Breakthrough Awaits Verification

Currently, the digital health service market in which 160 Health operates is experiencing exponential growth.

NewTimeSpace notes that the 2026 Government Work Report clearly stated the intention to "deepen and expand 'AI Plus,'" and "promote the large-scale commercial application of AI in key industries," while including biopharmaceuticals as an emerging pillar industry. The draft outline of the 15th Five-Year Plan also proposed seizing the commanding heights of AI industrial applications.

The continuous rise in 160 Health's stock price is essentially a resonance of four factors: the verification of a performance turning point, the breakthrough of the AI strategy, the industry’s upward cycle, and the catalyst of the Stock Connect.

According to Frost & Sullivan, the overall digital health services market is expected to increase from RMB 221.5 billion in 2024 to RMB 706.8 billion in 2029, a compound annual growth rate (CAGR) of 26.1%.

However, within this rapidly growing "blue ocean," 160 Health faces competition from traditional internet healthcare giants, tech conglomerates with cross-sector layouts, and startups focusing on vertical tracks.

The digital health service market is currently highly fragmented, with the top 15 platforms accounting for only 6.0% of the total market share. 160 Health’s current competitors include JD Health, AliHealth, Ping An Good Doctor, Fangzhou Jianke (Ark Health), and Qingsong Health.

Industry giants such as JD Health, as the pharmaceutical e-commerce leader, possess the most comprehensive SKU range and serve over 120 million users in chronic disease management; relying on JD Group’s logistics and supply chain, it holds an absolute leading position. AliHealth leverages the Alipay entry point to build a closed loop of "medical search-consultation-drug delivery" with extremely strong user reach. Ping An Good Doctor utilizes Ping An Group’s "medical-insurance synergy" ecosystem, with over 400 million registered users and its AI digital doctor "Ping An Xin Yi," possessing unique advantages in integrating insurance and medical services.

NewTimeSpace understands that 160 Health connects over 40,000 medical institutions, including a large number of Grade III Class A hospitals. The hospital SaaS systems the company has cultivated for years are the most ready-made "operating systems" for AI to land in the Chinese medical scenario.

Currently, 160 Health's value foundation is clear: AI cooperation verification with 82 public hospitals, confirmation of a profitable business model, and the liquidity dividend brought by the Stock Connect. Together, these elements form market expectations for its revaluation from a "registration platform" to a "medical AI gateway."

However, in a competitive landscape surrounded by giants, whether 160 Health can transform its "connector" advantage into a sustainable business model and turn AI product breakthroughs into true competitive barriers remains to be tested by time.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.